TGA seeks input on biosimilar naming in Australia

August 1, 2017

 

 

 

The TGA consultation paper can be found here.  

 

The TGA paper outlines the biosimilar naming conventions implemented in EU (INN), Japan (BSn), and the planned US 4 letter biologics suffix, and seeks input on whether something beyond the current approved Australian biological name (the INN where available) is required for Australia.

 

The TGA puts this naming initiative in the broader context of policies "to encourage update of biosimilar medicines" in Australia, including the 2015 Biosimilar Awareness Initiative, and recent 2017-2018 budget initiatives supporting biosimilar update in Australia.  Click here for further information.

 

 

 

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags